



Investor Insights

JMM & ÉTHICA CAPITAL

INNOVATION & INVESTMENT INSIGHTS LUNCH

Highlighting Innovative Companies and
Investment Opportunities

Thursday, 2 May 2024

12:00 PM - 3:00 PM

Establishment Ballroom, Sydney

JMM

JANE MORGAN MANAGEMENT

JMM delivers over 17 years' experience as investor relations and media communications advisors, with an award-winning team of account directors, copywriters, creatives, designers and digital marketers to provide ASX listed companies with a full suite of traditional and digital services, facilitating more effective communications with shareholders and investors.

www.janemorganmanagement.com.au

éthica | capital.

Ethica capital provides access to equity, debt and carbon-based financing at scale to sectors transitioning to sustainable business operations. Their advisory services span across debt, equity, carbon financing, corporate governance, media relations, supply chain development and enhancement. Ethica combines technical expertise and funding that aligns with your environmental and humanitarian goals, empowering businesses to achieve greater success and create a meaningful positive impact.

www.ethica.capital

COMPANIES PRESENTING

ASX:BXN

Bioxyme

Bioxyme Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

e: sam@breathelivesciences.com



ASX:BB1

blinklab

Australia-based BlinkLab (ASX:BB1) is focused on transforming mental healthcare through an AI-enabled smartphone application, a breakthrough technology developed at Princeton University.

The company's innovative approach leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old.

Once approved by the regulators, this cutting-edge digital technology is poised to capture the imagination of both investors and major pharmaceutical companies, eager to embrace transformative solutions in healthcare.

e: brian@blinklab.org



ASX:CYP

cynata
therapeutics

Cynata Therapeutics Limited (ASX:CYP) is advancing Cymerus™, a proprietary stem cell platform, for scalable production of high-quality mesenchymal stem cell (MSC)-based therapies. Their lead candidate, CYP-001, has shown promise in treating steroid-resistant acute graft-versus-host disease (GvHD), with ongoing trials for GvHD, osteoarthritis, and diabetic foot ulcers (DFU). Cymerus technology offers advantages over conventional methods by generating consistent MSCs from a single cell bank, with potential applications across various diseases.

e: kilian.kelly@cynata.com



ASX:IMU

IMUGENE
Developing Cancer Immunotherapies

Imugene (ASX:IMU) is a clinical stage immunology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate solid tumours and blood cancers. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

e: info@imugene.com



ASX:BDX



BCAL Diagnostics (ASX:BDX), founded in 2010 and headquartered in Sydney, is an Australian company committed to the early and accurate detection of breast cancer. Through its pioneering work, BCAL has developed a non-invasive blood test that shows promising results in diagnosing breast cancer, irrespective of breast tissue density. This test is designed to complement existing imaging technologies and aims to become a primary monitoring and screening tool for women worldwide. With over two million new breast cancer cases diagnosed globally each year, BCAL is poised to significantly enhance patient outcomes.



Jayne Shaw
Executive Chair

e: mhughes@bcaldiagnosics.com

ASX:ELS



Elsight (ASX:ELS) Elsite delivers Connection Confidence with proprietary bonding connectivity that incorporates both software and hardware elements to deliver reliable, secure, high bandwidth communications - even in the most challenging areas for stationary, portable, or actively mobile situational requirements. Elsite provides robust, secured connectivity to unmanned aerial and ground systems manufacturers, operators, and integrators globally.



Yoav Amitai
CEO

e: yoava.a@elsight.com

ASX:4DS



4DS Memory Limited (ASX: 4DS), with facilities located in Silicon Valley, is a semiconductor technology company bringing high bandwidth, high endurance, non-volatile memory to advanced CMOS process nodes. Its technology, known as Interface Switching ReRam, features tunable persistence and low energy per bit for today's most challenging compute intensive and AI processor applications. Established in 2007, 4DS owns a patented IP portfolio, comprising 34 USA patents, and is the first company to develop Area based ReRam, also known as PCMO, on an advanced CMOS processing node. 4DS has a joint development agreement with Western Digital subsidiary HGST, a global leader in storage solutions, and a development agreement with Belgium-based imec - a world leading research and innovation hub in nano electronics and digital technologies.



Howard Digby
Non-Executive Director

e: howard.digby@4dsmemory.com

ASX:WHK



WhiteHawk (ASX:WHK) developed the first cloud, AI/ML based cyber risk monitoring, prioritization and mitigation online cyber security exchange, democratizing access for all companies and organizations to address their Digital Age Risks and those of their suppliers/vendors, continuously and cost-effectively. WhiteHawk's 100% automated product lines include one-time or annual subscriptions for a Cyber Risk Program (one Enterprise) or Cyber Risk Radar (portfolio of Organizations or Suppliers) and virtual Cyber Consults tailored to Client Needs. Via the WHK online cyber security exchange, the Company also continuously vets and offers a breadth of AI/ML and Quantum next generation cyber risk and security solutions via an online Marketplace, enabling all businesses and organizations to take smart action against cybercrime, fraud, and disruption, for themselves, their clients and across their supply chains, on an ongoing basis with demonstrated resource savings.



Terry Roberts
Founder and CEO

e: twr@whitehawk.com

ASX:PPS



Praemium (ASX:PPS) was established in 2001 with the mission to simplify and streamline the complex and time-consuming process of wealth management. Recognising the potential for technology to revolutionise the market, Praemium set out to develop a next-generation platform that provides an exceptional client experience.



David Coulter
CFO

Through collaboration with wealth management professionals, Praemium crafted its platform to offer maximum flexibility, allowing advisers and private wealth managers to tailor solutions to meet the needs of clients both big and small across custody and non-custody solutions to provide a unified view of a client's total wealth portfolio on a single platform. Today, Praemium's platform administers and reports on over \$285 billion in FUA for some of Australia's largest and most reputable institutions, private wealth firms and advice practices. With the goal of providing the most comprehensive and engaging investment and reporting experience for advisers to efficiently manage the wealth of Australians, Praemium is dedicated to delivering innovative technology and exceptional service to its clients.

e: david.coulter@praemium.com



NOTES

Bioxyne (ASX:BXN)

BlinkLab (ASX:BB1)

Cynata Therapeutics (ASX:CYP)

Imugene (ASX:IMU)

Bcal Diagnostics (ASX:BDX)

Elsight (ASX:ELS)

4DS (ASX:4DS)

Whitehawk (ASX:WHK)

Praemium (ASX:PPS)

Additional notes:





Suite 201 Level 2, 234 George Street,
Sydney NSW 2000

info@janemorganmanagement.com.au
www.janemorganmanagement.com.au

éthica | capital.

Level 26, 44 Market Street,
Sydney NSW 2000

hello@ethica.capital
www.ethica.capital